Copyright
©The Author(s) 2022.
World J Clin Cases. Mar 26, 2022; 10(9): 2818-2828
Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2818
Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2818
Figure 7 The level of programmed death ligand-1 protein was detected using immunohistochemistry by the Dako programmed death ligand-1 immunohistochemistry 22c3 PharmDx kit.
A: Hematoxylin and eosin staining of the specimen, shown at × 100 original magnification; B: Negative control for the test, shown at × 200 original magnification; C: Positive control for the test, shown at × 200 original magnification; D: Immunohistochemistry revealed that this patient was positive for programmed death ligand-1 (PD-L1) in the cytomembrane of tumor cells (trehalose-6-phosphate synthase = 20%, cervical pedicle screws = 22), shown at × 200 original magnification. The black arrows indicate cells with high PD-L1 expression.
- Citation: Pan D, Li TP, Xiong JH, Wang SB, Chen YX, Li JF, Xiao Q. Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review. World J Clin Cases 2022; 10(9): 2818-2828
- URL: https://www.wjgnet.com/2307-8960/full/v10/i9/2818.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i9.2818